Medical Disorders
Basic InformationLookupsLatest News
Insurance Often Covers Ivermectin for COVID, Even Though Drug Doesn't WorkCOVID Cases Surge Again in U.S. Nursing HomesCBD and Cannabis Products for Acne, Psoriasis? Buyer Beware, Dermatologists SayCarbon Monoxide Deaths Soar During Power OutagesAHA News: Transplanting Pig Hearts Into Humans Offers Promise – and PerilCOVAX Program Has Now Sent 1 Billion COVID Vaccines to Poorer NationsCOVID Fatigue: Are You Among the 'Vaxxed & Done'?CDC Advises N95s as Best Masks Against CoronavirusYou Don't Have to Be a Smoker to Get Lung CancerSkipping COVID Vaccine in Pregnancy Brings Big Risks to Mothers, BabiesMasks Cut Distance Coronavirus Travels in Half, Study Finds1 in 10 People With COVID Still Infectious After 10 Days: StudyWorried About Omicron? Expert Offers Tips on Going Out SafelySupreme Court Blocks Biden's Vaccine Mandate for Large EmployersCould the 'Mono' Virus Help Trigger Multiple Sclerosis?AHA News: Obesity Harms Brain Health Throughout Life – Yet Scientists Don't Know WhyWhite House May Soon Offer 'High-Quality' Masks to AmericansCOVID Hospitalizations Rising in Kids Too Young for VaccineProgress on Lung Cancer Drives Overall Decline in U.S. Cancer DeathsNearly 600,000 U.S. Kids Had COVID Last WeekWildfires Plus Heat Make Breathing Dangerous in America's WestHow Safe Is a 'Holiday' From Bone-Strengthening Meds?White House to Give Schools 10 Million Free COVID Tests Every MonthBinaxNOW Test Catches COVID Infection in Many People, Study ShowsU.S. May Soon See Sharp Drop in Omicron Cases, Experts SayAs Omicron Rages, How Important Are Case Counts Anymore?Americans Should Avoid Travel to Canada: CDCRed Cross Says U.S. Blood Supply at Dangerously Low LevelPfizer Says Omicron-Specific Vaccine Ready by MarchRain or Shine, Allergies Are Tough. What's the Link to Weather?U.S. Insurers Must Cover 8 COVID At-Home Tests a Month: White HouseU.S. COVID Hospitalizations Pass Last Winter's PeakIn Breakthrough Transplant, Man Receives Genetically Modified Pig HeartExposure to Common Cold Might Help Shield Against COVIDDrug Combo Boosts Outcomes for Advanced MelanomaDo Not Use At-Home COVID Test Swabs in the Throat: FDAEven Symptom-Free, People With Omicron Much More Likely to Spread COVID: StudiesWant to Avoid Glaucoma? Look at What You EatNew Worry: 'Flurona,' When COVID Meets the FluAmid COVID Test Shortages, Price Gouging Is on the RiseNeed an At-Home COVID Test? Here's Help Finding and Using OneKnow Your Thyroid FactsFDA Shortens Time to Booster After Moderna Vaccine to 5 MonthsCOVID Vaccine May Temporarily Add 1 Day to Menstrual Cycle: StudyHospitals Are Rationing COVID Pills, Infusions as Cases RiseBreakthrough COVID Cases Overwhelmingly Mild for Vaccinated People: StudySupreme Court Hears Arguments on Biden's Vaccine Mandate for Big BusinessMore Evidence That State Lotteries Didn't Boost Vaccination RatesWhite House Finalizes Plan to Send Americans Free COVID Rapid TestsModerna CEO Says 4th COVID Dose May Be Needed Next Fall
Questions and AnswersVideosLinksBook Reviews
Related Topics

Men's Health
Women's Health

How Safe Is a 'Holiday' From Bone-Strengthening Meds?

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Jan 12th 2022

new article illustration

WEDNESDAY, Jan. 12, 2022 (HealthDay News) -- People on bone-protecting drugs often take breaks from them for a few years. Now a new study finds that a "holiday" from the medication risedronate (Actonel) may come with a slightly increased risk of hip fracture.

Researchers found that compared with a drug holiday from alendronate (Fosamax), taking a few years off from risedronate came with an 18% higher risk of hip fracture.

The absolute difference was small: 3.6% of patients on holiday from risedronate suffered a broken hip, versus 3% of those taking time off from alendronate.

But experts said the findings do suggest that people on a risedronate holiday should be reassessed and possibly restart the medication sooner than those who had been on alendronate.

Both risedronate and alendronate belong to a medication class called bisphosphonates. They are widely prescribed to people with the bone-thinning disease osteoporosis, to reduce the risk of fractures.

After years of use, though, the medications can have rare, but serious side effects -- namely, fractures of the thigh bone or a breakdown of bone in the jaw.

So doctors often recommend a holiday from bisphosphonates, with a reevaluation after two to three years.

That hiatus is considered safe for patients at relatively lower risk of fractures because bisphosphonates "bind" to bone, and continue to have protective effects after they are stopped.

However, risedronate and alendronate do have differences: Risedronate has a weaker "binding affinity" to bone, explained Kaleen Hayes, the lead researcher on the study and an assistant professor at Brown University School of Public Health.

The question, she said, has been whether risedronate's protection against fracture wanes a bit quicker during a medication holiday.

The new findings -- published Jan. 11 in the Annals of Internal Medicine -- suggest it does.

For the study, Hayes and colleagues used a health care database covering Ontario residents age 65 and up. They focused on more than 50,000 people who had used either risedronate or alendronate for at least three years before taking a holiday.

Roughly 25,000 risedronate users were each compared against an alendronate user with similar characteristics.

Overall, patients on holiday from risedronate had an 18% higher risk of hip fracture, though the difference was not apparent right away. It emerged two years into the medication hiatus, Hayes said.

Current recommendations say patients who have been taking bisphosphonates for three to five years can consider a holiday, with a "reassessment" after two to three years.

That involves looking at factors such as whether a patient has developed a health condition or started a medication that can reduce bone density, explained Dr. Linda Russell, who directs the Osteoporosis and Metabolic Bone Health Center at the Hospital for Special Surgery in New York City.

Russell, who reviewed the findings, said they are not surprising, given differences in how the two medications "stick" to bone. But they imply that risedronate users may need to restart treatment a little sooner than those on holiday from alendronate, she said.

"This is an important piece of work that adds a useful piece to the puzzle," said Dr. Kenneth Lyles, president of the board of trustees for the nonprofit Bone Health and Osteoporosis Foundation in Arlington, Va.

He said patients on holiday from risedronate should talk to their doctor about how to reassess, which might include doing a bone density measurement as early as one year into the hiatus.

Follow-up is key for all patients, however. Bisphosphonates are "very good" drugs, Lyles noted, but they do not cure osteoporosis.

"Osteoporosis does not go away," he said. "We can only reduce the risk of fracture."

The current findings do not imply that alendronate is the "better" bisphosphonate or should be the preferred choice, all three experts said.

Risedronate may be less likely to cause heartburn, Russell said. And unlike alendronate, Hayes noted, it comes in a once-a-month formulation and a weekly delayed-release version that does not have to be taken on an empty stomach.

Russell also emphasized that medication is part of the story. People with balance problems, she noted, may want to talk to their provider about exercises or physical therapy that can help with those issues.

"These medications do not completely prevent fractures," Russell said. "They lower the risk."

More information

The Bone Health and Osteoporosis Foundation has advice on preventing fractures.

SOURCES: Kaleen Hayes, PharmD, PhD, assistant professor, health services, policy and practice, Brown University School of Public Health, Providence, R.I.; Kenneth Lyles, MD, president, board of trustees, Bone Health and Osteoporosis Foundation, Arlington, Va., and geriatric medicine specialist, professor, medicine, Duke University School of Medicine, Durham, N.C.; Linda Russell, MD, rheumatologist and director, Osteoporosis and Metabolic Bone Health Center, Hospital for Special Surgery, New York City; Annals of Internal Medicine, Jan. 11, 2022, online


Amazon Smile


Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.


powered by centersite dot net